Abstract
Septic cardiomyopathy (SC) is a lethal complication of sepsis characterized by cardiac dysfunction. While exercise is known to be cardioprotective, the underlying molecular mechanisms remain elusive. This study identifies ApoA1tide, a novel exercise-derived peptide (exerkine) discovered through mouse plasma peptidomic screening. ApoA1tide was found to mitigate lipopolysaccharide (LPS)-induced SC by enhancing cardiac function and reducing inflammation, apoptosis, and oxidative stress. Mechanistically, ApoA1tide upregulates the transcription factor C/EBPβ, which promotes the expression of autophagy-related genes (LC3B, Atg3, Atg4b, Atg7). These findings suggest that ApoA1tide exerts its protective effects by enhancing C/EBPβ-mediated autophagy, offering a potential therapeutic strategy for SC.
Introduction: The Challenge of Septic Cardiomyopathy
Sepsis triggers a systemic inflammatory response that often leads to Septic Cardiomyopathy (SC), a condition marked by severe myocardial depression. Current clinical management is primarily supportive, as the specific molecular drivers—including oxidative stress and uncontrolled inflammation—are not fully understood. Exercise preconditioning is a well-established protective factor against cardiovascular distress during sepsis, mediated by "exerkines" released during physical activity. However, identifying the specific exerkines and their downstream pathways has been a significant challenge in cardiovascular research.
Discovery of ApoA1tide
To identify potential cardioprotective exerkines, researchers employed a multi-omics approach. Mice underwent a three-month swimming regimen, after which their blood plasma was analyzed using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
The screening identified 60 differentially expressed peptides. Among these, a 6-amino-acid fragment derived from Apolipoprotein A1 (ApoA1), named ApoA1tide, was significantly upregulated in the exercise group. While full-length ApoA1 is known for lipid transport, this specific peptide fragment appears to have a targeted role in cardiomyocyte protection.
Mechanistic Insights: C/EBPβ and Autophagy
RNA sequencing of cardiomyocytes treated with ApoA1tide identified CCAAT/enhancer-binding protein β (C/EBPβ) as the primary target. ApoA1tide upregulates C/EBPβ, which acts as a master transcriptional switch for cellular "cleanup" or autophagy.
As shown in the mechanism above, ApoA1tide enters the cardiomyocyte and increases C/EBPβ levels in the nucleus. This leads to the transcription of essential autophagy genes, including LC3B, Atg3, Atg4b, and Atg7. The resulting increase in autophagic flux allows the cell to clear damaged mitochondria and reactive oxygen species (ROS), thereby inhibiting the inflammatory response and preventing apoptosis (programmed cell death).
Key Results
- Survival and Cardiac Function: In murine models of sepsis (LPS-induced), ApoA1tide pretreatment significantly improved 7-day survival rates and restored Left Ventricular Ejection Fraction (LVEF) to near-baseline levels.
- Cellular Protection: The peptide reduced the Bax/Bcl-2 ratio (a marker of apoptosis) and lowered oxidative stress in both rat (NRCMs) and human (AC16) cardiomyocyte cell lines.
- Human Translation: A humanized version of the peptide (hm-ApoA1tide), differing by only two amino acids, demonstrated similar protective effects in human cell models, suggesting high potential for clinical translation.
Limitations and Future Directions
While promising, the study has limitations. The use of LPS to simulate sepsis is a standard but simplified model; future research should utilize more complex models like cecal ligation and puncture (CLP) to better mimic human polymicrobial sepsis. Additionally, the specific cell-surface receptor that ApoA1tide binds to remains unidentified. Further investigation into the exact transcriptional or post-translational mechanics of C/EBPβ regulation by this peptide is also required to fully map this therapeutic pathway.
Summary updated